ENTITY
Everest Medicines

Everest Medicines (1952 HK)

155
Analysis
Health Care • China
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative pharmaceutical products and vaccines. The company has a product pipeline across renal, anti-infective, autoimmune, critical care, cardiovascular, and ophthalmic diseases, including products like Nefecon (TarpeyoTM) and Eravacycline (Xerava). Everest Medicines was founded in 2017 and is headquartered in Shanghai, China.
more
bullish•Kioxia Holdings
•16 Jun 2025 08:08

ECM Weekly (16 June 2025) - Haitian, Sanhua, Kitazato, Primo, Kioxia, Xtalpi, Horizon, Keymed, Wuxi

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
655 Views
Share
•15 Jun 2025 10:15

HK Connect Flows Weekly (Jun 13th): BYD, Meituan, CCB, Innovent Biologics, Petrochina, Tencent

We analyzed the Hong Kong Connect Scheme for last week and highlighted flows for BYD, Meituan, CCB, Innovent Biologics, Petrochina, Tencent,...

Logo
929 Views
Share
bullish•Wuxi Biologics
•13 Jun 2025 18:46

Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain

Wuxi Biologics Holdings is looking to raise up to US$288m by selling about 2% of Wuxi Biologics (2269 HK). This will be the 17th placement in the...

Logo
799 Views
Share
•12 Jun 2025 18:15

Everest Medicine Placement: Another Sell-Down by CBC, Some Caution Warranted

Everest Medicine aims to raise around US$150m in a secondary sell-down of shares conducted by CBC Group. In this note, we comment on the deal...

Logo
808 Views
Share
•04 May 2025 10:05

HK Connect Flows Weekly (May 2nd): Meituan, Tencent, Ping An Insurance, BYD, SMIC, China Mobile

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Meituan, Tencent, Ping An Insurance, BYD, SMIC, China...

Logo
566 Views
Share
x